Clinical observation of sintilimab combined with bevacizumab in the treatment of advanced unresectable liver cancer after transcatheter arterial chemoembolization
- VernacularTitle:信迪利单抗联合贝伐珠单抗用于晚期不可切除肝细胞癌患者TACE后的临床观察
- Author:
Lei WEI
1
;
Yan LIU
2
;
Yan WU
3
;
Wu WEI
1
;
Ming QIANG
1
Author Information
1. Dept. of Oncology，No. 901 Hospital of Joint Service Support Force of PLA，Hefei 230031，China
2. Dept. of Oncology，Hefei Cancer Hospital of Chinese Academy of Sciences，Hefei 230022，China
3. Dept. of Oncology，the Second Hospital of Anhui Medical University，Hefei 260301，China
- Publication Type:Journal Article
- Keywords:
hepatocellular carcinoma;
advanced unresectable
- From:
China Pharmacy
2024;35(24):3029-3034
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To observe the efficacy， tumor markers， immune function and safety of sintilimab combined with bevacizumab in the treatment of advanced unresectable hepatocellular carcinoma （HCC） after transcatheter arterial chemoembolization （TACE）. METHODS A total of 120 patients with advanced unresectable HCC in No.901 Hospital of Joint Service Support Force of PLA from June 2022 to December 2022 were selected and divided into control group （n＝60） and study group （n＝60） using the random number method. Both groups received TACE. The control group was treated with Sorafenib mesylate tablets， and the study group was treated with Sintilimab injection combined with Bevacizumab injection. The clinical efficacy， tumor markers （alpha-fetoprotein， carcinoembryonic antigen， carbohydrate antigen 19-9）， immune function indexes （CD3+， CD4+， CD8+， CD4+/ CD8+）， and adverse reactions of the two groups were observed after three months of treatment. RESULTS After the treatment， there was no significant difference between the two groups in objective remission rate， disease control rate， mortality rate， or median progression-free survival （P＞0.05）. The median overall survival of the study group was significantly longer than control group （P＜0.05）. After treatment， the levels of tumor markers and immune function （except for CD8+） in both groups were significantly lower than before treatment； the average levels of tumor markers in the study group were significantly lower than control group， while the levels of immune function （except for CD8+） were significantly higher than control group （P＜0.05）. There was no statistically significant difference in the incidence of grade 3 adverse reactions， as well as the incidence of grade 1-2 adverse reactions such as hypothyroidism and immune-related pneumonia between the two groups （P＞0.05）. CONCLUSIONS For advanced unresectable HCC patients undergoing TACE， bevacizumab combined with sintilimab can effectively improve immune function， reduce tumor markers and improve the overall survival with good safety.
